Our initial discovery cohort consisting of only 23 subjects, was considered small and lacked proper documented follow-up, therefore, the relationship between KDM5B expression and tumor progression using the initial cohort data was subjected to further exploration in a larger, independent validation cohort of 270 breast cancer patients TMA with longer follow-up, which included overall disease-specific survival. Here, KDM5B is linked to breast cancer.